Evaluation of the Safety and Efficacy of REBORN System for Lipolysis Treatment

LIPOLYSIS Clinical Trial

Official title:

EVALUATION OF THE SAFETY AND EFFICACY OF REBORN LED SYSTEM FOR NON-INVASIVE LIPOLYSIS TREATMENT

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05507528
• Other study ID #: RB-LF-01
• Status: Completed
• Phase: N/A
• Start date: June 30, 2022
• Est. completion date: November 11, 2023

Study information

• Verified date: February 2024
• Source: Lightfective Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Lightfective ReBorn System is intended for non-invasive lipolysis of the flanks in individuals with a Body Mass Index (BMI) of 30 or less. The device is intended to affect the appearance of visible fat bulges in the flanks.

Description:

Body countering and fat reduction treatment are considered to be one of the most popular aesthetic procedures. The Lightfective' ReBorn LED System provides non-invasive fat reduction treatment. The primary efficacy objective is to demonstrate fat reduction in the treated area after treatment with the ReBorn LED system. study population, Healthy subjects who seek for fat reduction treatments in the flanks area. Each subject will undergo 2 treatment visits (one month apart) and follow-up visits.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 107
• Est. completion date: November 11, 2023
• Est. primary completion date: November 11, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 22 Years and older

Eligibility

Inclusion Criteria:

1. Male or female subjects > 22 years of age.

2. Subject has clearly visible fat on the flanks area.

3. Subject has not experienced weight change exceeding 4.5kg in the preceding month.

4. Subject agrees to maintain their weight (i.e., within 2.25kg) by not making any major changes in their diet or lifestyle during the course of the study.

5. Subject is willing and able to comply with protocol requirements and all study visits

6. Subject has provided a written informed consent

Exclusion Criteria:

1. Subject underwent a prior surgical procedure(s) in the area of intended treatment within the past 6 months.

2. Subject underwent a prior invasive fat reduction procedure (e.g., liposuction, abdominoplasty, mesotherapy) in the area of intended treatment within the past year.

3. Subject underwent a prior non-invasive fat reduction procedure in the area of intended treatment within the past 6 months.

4. Subject has a known history of subcutaneous injections into the area of intended treatment (e.g., clexane, insulin) within the past month.

5. Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria.

6. Subject has a known history of Reynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin.

7. Subject has a history of bleeding disorder, or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising.

8. Subject body mass index (BMI) exceeds 30. BMI is defined as weight in kg divided by the square of the height in cm.

9. Subject is taking or has taken diet pills or supplements within the past month.

10. Subject has any dermatological conditions or scars in the location of the treatment sites that may interfere with the treatment or evaluation.

11. Subject is pregnant or intending to become pregnant in the next 6 months.

12. Subject is lactating or has been lactating in the past 6 months.

13. Subject is unable or unwilling to comply with the study requirements.

14. Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device.

15. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

16. Subject is currently taking weight reduction medications (e.g., Saxenda).

17. Subject is currently taking GLP-1 receptor agonist medications (e.g., Victoza).

Related Conditions & MeSH terms

• LIPOLYSIS

Intervention

Device:
• reborn treatment
Fat reduction treatments with the ReBorn LED System visit - include the treatment procedure

Locations

Country	Name	City	State
Israel	Herzelia Medical Center - Tal Nachliely clinic	Kiryat Bialik
Israel	rabin medical center - campus Hasharon	Petah tikva
United States	Tennessee Clinical Research Center	Tennessee	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
Lightfective Ltd

Countries where clinical trial is conducted

United States,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fat reduction	to demonstrate fat reduction in the treated area after treatment with the ReBorn LED system.	20 weeks
Primary	Blinded reviewers evaluation	subject's pre and post-treatment photographs will be presented in randomized order to blinded reviewers for evaluation.; Subject is considered "success" if at least two out of the three evaluators correctly identify photographs order.	20 weeks
Secondary	safety evaluation	The safety of the ReBorn LED System will be demonstrated by serious adverse event during the study.	20 weeks